O'Donnell J A, Gelone S P
Department of Medicine, Medical College of Pennsylvania, Hahnemann University, School of Medicine, Philadelphia, USA.
Infect Dis Clin North Am. 2000 Jun;14(2):489-513, xi. doi: 10.1016/s0891-5520(05)70260-9.
The fluoroquinolone class of antimicrobial agents has expanded dramatically in the last 5 years and will continue to grow over the next decade. This article discusses the newer fluoroquinolones in detail, including pharmacokinetics, pharmacodynamics, safety, and drug interactions, and the spectrum of in vitro activity. Newer agents are compared and contrasted with the older ones, particularly ciprofloxacin and ofloxacin, and problems with liver toxicity and trovafloxacin are described. Finally, appropriate use of the fluoroquinolones is discussed, including their role in the treatment of urinary tract infections, sexually transmitted diseases, gastrointestinal infections, osteomyelitis, and respiratory tract infections.
在过去5年中,氟喹诺酮类抗菌药物种类大幅增加,并将在未来十年继续增长。本文详细讨论了新型氟喹诺酮类药物,包括药代动力学、药效学、安全性、药物相互作用以及体外活性谱。将新型药物与旧型药物,特别是环丙沙星和氧氟沙星进行了比较和对比,并描述了肝毒性和曲伐沙星的问题。最后,讨论了氟喹诺酮类药物的合理使用,包括它们在治疗尿路感染、性传播疾病、胃肠道感染、骨髓炎和呼吸道感染中的作用。